Bayer shares climbed more than 5% on Thursday after the company announced a major restructuring of its U.S. Roundup operations.
The German pharmaceutical and agricultural group will consolidate the business into a new unit called Ruveon. The announcement came less than a week after a U.S. Supreme Court ruling weakened thousands of state-level lawsuits linked to the weedkiller.
Ruveon to Manage the U.S. Roundup Business
Ruveon will remain part of Bayer and will oversee all aspects of Roundup sales in the United States.
Its responsibilities will include pricing, manufacturing, distribution and logistics.
Bayer said the restructuring forms part of the Crop Science division’s five-year strategy. The plan aims to improve growth, resilience and profitability.
The company believes Ruveon will operate with greater flexibility in a highly competitive, commodity-focused market.
Bayer Continues to Face Glyphosate Litigation
Bayer acquired Roundup through its $63 billion takeover of Monsanto in 2018.
However, the deal created significant legal and financial challenges. Thousands of lawsuits accused Monsanto of failing to warn customers about alleged cancer risks associated with glyphosate, Roundup’s main ingredient.
Bayer remains the only U.S. producer of glyphosate. The company has repeatedly argued that decades of scientific research support the safety of the herbicide when used as directed.
Supreme Court Ruling Reduces Legal Risks
In the Monsanto v. Durnell case, the U.S. Supreme Court ruled that federal law takes priority over state-level failure-to-warn claims.
That legal argument had supported around 200,000 claims filed against the company.
The ruling could significantly strengthen Bayer’s efforts to control its remaining glyphosate liabilities.
Deutsche Bank Upgrades Bayer Stock
Following the court decision, Deutsche Bank upgraded Bayer stock from Hold to Buy.
The bank also raised its price target to €60.
Analysts described the ruling as a critical development for Bayer’s efforts to contain its glyphosate exposure. They also highlighted a proposed class-action settlement announced earlier in the year.
According to Deutsche Bank, the Supreme Court decision makes it more likely that the settlement will remain in place. Analysts believe Bayer’s potential glyphosate costs could now stay within its existing financial provisions.
Investors May Shift Their Focus to Bayer’s Growth
As litigation concerns ease, analysts expect investors to pay more attention to Bayer’s underlying businesses.
Deutsche Bank sees improving growth prospects in both the Crop Science and Pharmaceuticals divisions.
Reduced legal uncertainty could also give Bayer more freedom to restructure its wider portfolio.
Bayer Restructuring Could Unlock More Value
Analysts suggested that Bayer could eventually consider spinning off its Crop Science division.
The company could also explore the sale of its Consumer Health business.
Deutsche Bank estimated that these measures could unlock a combined value of around €84 per Bayer share. That figure was significantly higher than the company’s stock price when the report was published.
Bayer Earnings Scheduled for August
Bayer is expected to release its second-quarter 2026 financial results on August 4.
Investors will closely examine the performance of the Crop Science and Pharmaceuticals divisions, as well as any updates on glyphosate litigation and Bayer’s restructuring plans.
